NAFLD/MASLD

Clinical trials for NAFLD/MASLD explained in plain language.

Never miss a new study

Get alerted when new NAFLD/MASLD trials appear

Sign up with your email to follow new studies for NAFLD/MASLD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug efruxifermin aims to reverse liver scarring in NASH patients

Disease control Ongoing

This Phase 3 study tests whether efruxifermin, given as a weekly shot, is safe and can improve liver health in 700 adults with NASH/MASH (a type of fatty liver disease). Participants receive either the drug or a placebo. The study tracks side effects and measures changes in liver…

Matched conditions: NAFLD/MASLD

Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control

Last updated Jun 27, 2026 12:26 UTC

NAFLD/MASLD

Get alerted when new NAFLD/MASLD trials appear

New drug efruxifermin aims to reverse liver scarring in NASH patients